What is the role of the hyper-CVAD regimen in the treatment of lymphoblastic lymphoma?

Updated: Sep 10, 2019
  • Author: Joseph M Tuscano, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print


Encouraging results have been obtained with another regimen commonly used for ALL, hyper-CVAD (fractionated cyclophosphamide vincristine, Adriamycin [doxorubicin], and dexamethasone), which was used in patients with lymphoblastic lymphoma. [11] This regimen generated responses in 100% of patients, 91% being complete, and producing a 3-year progression-free of 66% and an overall survival of 70%.

Despite high initial remission rates, 40-60% of adults eventually relapse, with relapse rates considerably higher in patients with poor prognostic features (see Prognosis and Prognostic Factors). Several studies have examined the role of both autologous and allogeneic stem cell transplantation in first and second remission, as well as in patients with refractory disease.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!